Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Current Assets (2016 - 2025)

Assembly Biosciences has reported Current Assets over the past 11 years, most recently at $254.5 million for Q4 2025.

  • Quarterly results put Current Assets at $254.5 million for Q4 2025, up 120.38% from a year ago — trailing twelve months through Dec 2025 was $254.5 million (up 120.38% YoY), and the annual figure for FY2025 was $254.5 million, up 120.38%.
  • Current Assets for Q4 2025 was $254.5 million at Assembly Biosciences, up from $236.8 million in the prior quarter.
  • Over the last five years, Current Assets for ASMB hit a ceiling of $254.5 million in Q4 2025 and a floor of $49.7 million in Q3 2023.
  • Median Current Assets over the past 5 years was $116.3 million (2024), compared with a mean of $133.6 million.
  • Biggest five-year swings in Current Assets: plummeted 56.84% in 2023 and later skyrocketed 141.12% in 2025.
  • Assembly Biosciences' Current Assets stood at $154.2 million in 2021, then plummeted by 37.12% to $97.0 million in 2022, then surged by 37.97% to $133.8 million in 2023, then decreased by 13.67% to $115.5 million in 2024, then soared by 120.38% to $254.5 million in 2025.
  • The last three reported values for Current Assets were $254.5 million (Q4 2025), $236.8 million (Q3 2025), and $77.5 million (Q2 2025) per Business Quant data.